ALK and non-small cell lung carcinoma: Here, we describe a case of a young never-smoker woman affected by advanced ALK-positive NSCLC who presented a dramatic clinical course to a sequential treatment with ALK TKIs, with an acquired resistance to crizotinib entailing primary resistance to brigatinib and lorlatinib.